Substantial improvements in survival have been seen in multiple myeloma (MM) over recent
years, associated with the introduction and widespread use of multiple novel agents and …

Tremendous progress in treatment and outcomes has been achieved across the whole
range of haematological malignancies in the past two decades. Although cure rates for …

Simple Summary In clinical trials, patients treated with idecabtagene vicleucel (ide-cel)
chimeric antigen receptor T-cell therapy (CAR T) have reported meaningful improvements in …

Introduction New therapies for multiple myeloma (MM) have improved life expectancy, but
health-related quality of life (HRQoL) data from patients with MM in the real-world setting are …

Background The clinical management of patients with relapsed or refractory multiple
myeloma is challenging and there is a paucity of tools to help clinicians make more informed …

Autologous stem cell transplantation (ASCT) is an integral part of the frontline therapy in
eligible multiple myeloma (MM) patients. The impact of ASCT on health-related quality of life …

Purpose The quality of patient-reported outcome (PRO) data can be compromised by non-
response (NR) to scheduled questionnaires, particularly if reasons for NR are related to …

Purpose Patients with relapsed and/or refractory multiple myeloma (RRMM) are living longer
due in part to changing treatment patterns. It is important to understand how changing …

New treatments have transformed multiple myeloma into a chronic disease. Hence, optimal
management of treatment and disease‐related complications remains a critical component …

Patients with relapsed/refractory multiple myeloma (RRMM) need proven subsequent
therapies after early-line lenalidomide treatment failure. The phase 2 MM-014 trial …